Paul Larson, MD

Neurosurgeon

Dr. Paul S. Larson is a neurosurgeon who specializes in the surgical treatment of movement disorders including Parkinson's disease and essential tremor, and psychiatric disorders including obsessive compulsive disorder and Tourette's syndrome. Larson sees patients in the UCSF Movement Disorders Clinic.

Larson earned a medical degree at the University of Arizona School of Medicine in 1995 and completed an internship and residency at the University of Louisville in Kentucky. His areas of research include the use of interventional MRI in deep brain stimulation surgery, the use of gene therapy to treat Parkinson's disease and the role of the basal ganglia in hearing. He is a professor of Neurological Surgery at UCSF, and chief of Neurosurgery and director of the Center for Advanced Neurosurgical Operative Procedures at the Veteran Affairs Medical Center in San Francisco. Larson has received two teaching awards at UCSF, authored numerous publications and edited two textbooks on functional neurosurgery.

Clinics

Movement Disorder and Neuromodulation Center
1635 Divisadero St., Suite 520
San Francisco, CA 94115
Neurology: (415) 353-2311
Neurosurgery: (415) 353-2071
Fax: (415) 353-9060

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title

Professor

More about Paul Larson

Education

University of Arizona Medical School 1995

Residencies

University of Louisville, School of Medicine, Neurological Surgery 2001

Fellowships

University of Louisville, Surgery 1996

Selected Research and Publications

  1. Talbott JF, Cooke DL, Mabray MC, Larson PS, Amans MR, Hetts SW, Wilson MW, Moore T, Salegio EA. Accuracy of image-guided percutaneous injection into a phantom spinal cord utilizing flat panel detector CT with MR fusion and integrated navigational software. J Neurointerv Surg. 2018 Apr 17.
  2. Kundishora AJ, Englot DJ, Starr PA, Martin AJ, Larson PS. Venous Thromboembolism during Interventional MRI-Guided Stereotactic Surgery. Stereotact Funct Neurosurg. 2018; 96(1):40-45.
  3. Southwell DG, Birk HS, Larson PS, Starr PA, Sugrue LP, Auguste KI. Laser ablative therapy of sessile hypothalamic hamartomas in children using interventional MRI: report of 5 cases. J Neurosurg Pediatr. 2018 Feb 16; 1-6.
  4. Larson PS, Starr PA, Martin AJ. Deep Brain Stimulation: Interventional and Intraoperative MRI Approaches. Prog Neurol Surg. 2018; 33:187-197.
  5. Southwell DG, Rutkowski MJ, San Luciano M, Racine C, Ostrem J, Starr PA, Larson PS. Before and after the veterans affairs cooperative program 468 study: Deep brain stimulator target selection for treatment of Parkinson's disease. Parkinsonism Relat Disord. 2018 Mar; 48:40-44.
  6. Martin AJ, Starr PA, Ostrem JL, Larson PS. Hemorrhage Detection and Incidence during Magnetic Resonance-Guided Deep Brain Stimulator Implantations. Stereotact Funct Neurosurg. 2017; 95(5):307-314.
  7. Srejic U, Larson P, Bickler PE. Little Black Boxes: Noncardiac Implantable Electronic Medical Devices and Their Anesthetic and Surgical Implications. Anesth Analg. 2017 07; 125(1):124-138.
  8. Larson PS, Willie JT, Vadivelu S, Azmi-Ghadimi H, Nichols A, Fauerbach LL, Johnson HB, Graham D. MRI-guided stereotactic neurosurgical procedures in a diagnostic MRI suite: Background and safe practice recommendations. J Healthc Risk Manag. 2017 Jul; 37(1):31-39.
  9. LaHue SC, Ostrem JL, Galifianakis NB, San Luciano M, Ziman N, Wang S, Racine CA, Starr PA, Larson PS, Katz M. Parkinson's disease patient preference and experience with various methods of DBS lead placement. Parkinsonism Relat Disord. 2017 Aug; 41:25-30.
  10. Larson PS, Vadivelu S, Azmi-Ghadimi H, Nichols A, Fauerbach L, Johnson HB. Neurosurgical laser ablation and MR thermometry: Risks of multisite workflow pattern. J Healthc Risk Manag. 2017 Apr; 36(4):7-18.
  11. Wharen RE, Okun MS, Guthrie BL, Uitti RJ, Larson P, Foote K, Walker H, Marshall FJ, Schwalb J, Ford B, Jankovic J, Simpson R, Dashtipour K, Phibbs F, Neimat JS, Stewart RM, Peichel D, Pahwa R, Ostrem JL. Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. Parkinsonism Relat Disord. 2017 Jul; 40:18-26.
  12. Rolston JD, Englot DJ, Starr PA, Larson PS. An unexpectedly high rate of revisions and removals in deep brain stimulation surgery: Analysis of multiple databases. Parkinsonism Relat Disord. 2016 Dec; 33:72-77.
  13. Ramos AD, Rolston JD, Gauger GE, Larson PS. Spinal Subdural Abscess Following Laminectomy for Symptomatic Stenosis: A Report of 2 Cases and Review of the Literature. Am J Case Rep. 2016 Jul 12; 17:476-83.
  14. Southwell DG, Narvid JA, Martin AJ, Qasim SE, Starr PA, Larson PS. Comparison of Deep Brain Stimulation Lead Targeting Accuracy and Procedure Duration between 1.5- and 3-Tesla Interventional Magnetic Resonance Imaging Systems: An Initial 12-Month Experience. Stereotact Funct Neurosurg. 2016; 94(2):102-7.
  15. Han SJ, Bankiewicz K, Butowski NA, Larson PS, Aghi MK. Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. Expert Rev Neurother. 2016 06; 16(6):635-9.
  16. Martin AJ, Larson PS, Ziman N, Levesque N, Volz M, Ostrem JL, Starr PA. Deep brain stimulator implantation in a diagnostic MRI suite: infection history over a 10-year period. J Neurosurg. 2017 Jan; 126(1):108-113.
  17. Marks WJ, Baumann TL, Bartus RT. Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer. Hum Gene Ther. 2016 07; 27(7):522-7.
  18. Rowland NC, Kalia SK, Kalia LV, Larson PS, Lim DA, Bankiewicz KS. Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Mol Ther Methods Clin Dev. 2016; 3:15051.
  19. Ostrem JL, Ziman N, Galifianakis NB, Starr PA, Luciano MS, Katz M, Racine CA, Martin AJ, Markun LC, Larson PS. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease. J Neurosurg. 2016 Apr; 124(4):908-16.
  20. Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, Kordower JH, Alterman R, Lozano AM, Lang AE. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.